[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-336755-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-336755-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","gold-nanorodassisted-theranostic-solution-for-nonvisible-residual-disease-in-bladder-cancer","Gold nanorod–assisted theranostic solution for nonvisible residual disease in bladder cancer","","Residual nonvisible bladder cancer after appropriate treatment drives relapse and progression due to technological and therapeutic constraints. This study evaluates feasibility of a theranostic approach enabling simultaneous detection and treatment of bladder cancer lesions smaller than one millimeter. The α5β1 integrin serves as a target, delivering urine-stable gold nanorods that enable photoacoustic visualization and irradiation-induced hyperthermia in an orthotopic preclinical model, supported by necrosis, survival outcomes, and computational modeling. The strategy aims to reduce residual disease risk, pending clinical validation.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/gold-nanorodassisted-theranostic-solution-for-nonvisible-residual-disease-in-bladder-cancer/336755/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/gold-nanorodassisted-theranostic-solution-for-nonvisible-residual-disease-in-bladder-cancer/336755.png","ImageObject",300,407,{"name":42,"@type":43},"Miles","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-24","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What problem does the study address in bladder cancer care?","Question",{"text":63,"@type":64},"Residual nonvisible bladder cancer after proper treatment can lead to tumor relapse and progression because current technologies and therapies have limitations in detecting and addressing very small lesions.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How are the gold nanorods used in the proposed theranostic solution?",{"text":68,"@type":64},"Targeted gold nanorods are delivered via an α5β1 integrin–directed approach to enable photoacoustic imaging of lesions smaller than one millimeter, followed by laser irradiation to induce GNR-assisted hyperthermia.",{"name":70,"@type":61,"acceptedAnswer":71},"What evidence supports the effectiveness and safety of the approach?",{"text":72,"@type":64},"The preclinical orthotopic model evaluates photoacoustic visualization, hyperthermia effects, necrosis of tumor mass, improved survival, and computational modeling to assess efficacy and safety.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},336755,1790750199,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":112,"preview_page_count":33,"preview_urls":145},13056703019404,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","RESEARCH ARTICLE  \nMEDICAL SCIENCES  \n OPEN ACCESS  \nGold nanorod–assisted theranostic solution for nonvisible residual disease in bladder cancer  \nPaolo Armanettia,1, Irene Locatellib,c,1, Chiara Venegonib,c , Elisa Alcherab,c, Beatrice Campanellad, Filippo Pederzolib,c,e, Mirko Maturif, Erica Locatellif, Silvia Tortorellaf, Flavio Curnisg , Angelo Cortig , Roberta Lucianòh, Massimo Onord , Andrea Saloniab,c,e, Francesco Montorsib,c,e, Marco Moschinib,c, Viktor Popovi, Jithin Josej , Mauro Comes Franchinif,2, Ean Hin Ooik,2, Luca Menichettia,2, and Massimo Alfanob,c,2  \nAffiliations are included on p. 11.  \nEdited by Guru Sonpavde, University of Central Florida, Orlando, FL; received June 10, 2024; accepted August 6, 2024 by Editorial Board Member Rakesh K. Jain  \nResidual nonvisible bladder cancer after proper treatment caused by technological and therapeutic limitations is responsible for tumor relapse and progression. This study aimed to demonstrate the feasibility of a solution for simultaneous detection and treatment of bladder cancer lesions smaller than one millimeter. The α5β1 integrin was identified asa specific marker in 81% of human high-grade nonmuscle invasive bladder cancers and used as a target for the delivery of targeted gold nanorods (GNRs). In a preclinical model of orthotopic bladder cancer expressing the α5β1 integrin, the photoacoustic imaging of targeted GNRs visualized lesions smaller than one millimeter, and their irradiation with continuous laser was used to induce GNR-assisted hyperthermia. Necrosis of the tumor mass, improved survival, and computational modeling were applied to demonstrate the efficacy and safety of this solution. Our study highlights the potential of the GNR-assisted theranostic strategy as a complementary solution in clinical practice to reduce the risk of nonvisible residual bladder cancer after current treatment. Further validation through clinical studies will support the findings ofthe present study.  \nbladder tumor | nanoparticles | photoacoustic imaging | hyperthermia | computational modeling  \nBladder cancer (BC) is the tenth most common cancer worldwide, with more than halfa million new diagnoses and 200,000 deaths every year (1). Approximately 75% of patients who are first diagnosed with BC have tumors confined either to the urothelium (noninvasive papillary carcinoma—Ta, and in situ carcinoma—CIS) or to the lamina propria (T1) and are classified as nonmuscle invasive bladder cancer (NMIBC) (2) . Guidelines for the clinical management of NMIBC involve endoscopic transurethral resection of bladder tumor (TURBT), usually followed by intravesical instillation ofadjuvant therapy (3). Unfortunately, patients with NMIBC often have a high tumor recurrence rate. At the second-look TURBT (i.e., \u003C90 d after the first TURBT), residual high-grade disease was still detected in 40% of patients, with high-grade Ta making up the majority of these cases (57%) (4) .  \nEven the use of the photodynamic diagnosis method (performed using blue light after preoperative intravesical instillation of hexaminolevulinic acid) concomitant to TURBT and early intravesical instillation of mitomycin C did not effectively reduce the frequency of NMIBC relapse, which stands up to 60% 3 y post-TURBT (5) . Hence, more than 200,000 NMIBC patients each year are expected to have BC relapses, which often require multiple intervention sessions/cycles and follow-ups in an attempt to eradicate the tumor. This, coupled with the high cost involved in TURBT (6), results in BC becoming the most expensive malignancy to treat over the lifetime of patients, with an annual expenditure of USD 10 billion (7, 8) . Consequently, reducing the recurrence rate of NMIBC relapses is a priority to improve quality of life and reduce the economic burden on patients and their caregivers.  \nTo improve the success of clinical management of NMIBC, two limitations need to be addressed. First, photodynamic diagnosis is ineffective in detect","cbCaitHeqwEc1szo","https://ap.wps.com/l/cbCaitHeqwEc1szo","pdf",4391663,12,"English","# Background\n## Nonvisible residual bladder cancer and recurrence\n## Limitations of current diagnostic and therapeutic approaches\n# Study Rationale\n## Need for detection and treatment below 1 mm\n# Targeting Strategy\n## α5β1 integrin as the marker for targeted gold nanorods\n# Preclinical Theranostic Workflow\n## Targeted photoacoustic imaging and laser-induced hyperthermia\n## Necrosis, survival, and computational modeling\n# Significance and Next Steps\n## Complementary clinical potential and need for validation","[{\"question\":\"What problem does the study address in bladder cancer care?\",\"answer\":\"Residual nonvisible bladder cancer after proper treatment can lead to tumor relapse and progression because current technologies and therapies have limitations in detecting and addressing very small lesions.\"},{\"question\":\"How are the gold nanorods used in the proposed theranostic solution?\",\"answer\":\"Targeted gold nanorods are delivered via an α5β1 integrin–directed approach to enable photoacoustic imaging of lesions smaller than one millimeter, followed by laser irradiation to induce GNR-assisted hyperthermia.\"},{\"question\":\"What evidence supports the effectiveness and safety of the approach?\",\"answer\":\"The preclinical orthotopic model evaluates photoacoustic visualization, hyperthermia effects, necrosis of tumor mass, improved survival, and computational modeling to assess efficacy and safety.\"}]","Gold nanorod–assisted theranostic solution for nonvisible residual disease in bladder cancer | PDF",1790016459,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f3094d37b5f19c23114a38ca21fd53a7.webp",983,1316,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/dc97d2b25a22a53dd2fbe4c943759ffe.webp",982,1315,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ca59ff517f07fb108448f00b5fb050d9.webp",981,1313,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bd146e6d4c120ec0c8f32aeac84a310b.webp",980,1312]